Tazemetostat: Targeting EZH2 in R/R Follicular Lymphoma

Opinion
Video

Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Related Content
Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.

FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma

Tim Cortese
June 18th 2025
Article

Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.

LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy

LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy

Tim Cortese
June 18th 2025
Article

LYL314 elicited a complete response rate of 72%, with 71% of responses lasting for 6 or more months in patients with large B-cell lymphoma in the third or later lines of therapy.